External evaluation of population pharmacokinetic models of vancomycin in large cohorts of intensive care unit patients

Tingjie Guo, Reinier M. van Hest, Luca F. Roggeveen, Lucas M. Fleuren, Patrick J. Thoral, Rob J. Bosman, Peter H. J. van der Voort, Armand R. J. Girbes, Ron A. A. Mathot, Paul W. G. Elbers

Research output: Contribution to journalArticleAcademicpeer-review

36 Citations (Scopus)


Dosing of vancomycin is often guided by therapeutic drug monitoring and population pharmacokinetic models in the intensive care unit (ICU). The validity of these models is crucial, as ICU patients have marked pharmacokinetic variability. Therefore, we set out to evaluate the predictive performance of published population pharmacokinetic models of vancomycin in ICU patients. The PubMed database was used to search for population pharmacokinetic models of vancomycin in adult ICU patients. The identified models were evaluated in two independent data sets which were collected from two large hospitals in the Netherlands (Amsterdam UMC, Location VUmc, and OLVG Oost). We also tested a one-compartment model with fixed values for clearance and volume of distribution, in which a clinical standard dosage regimen (SDR) was mimicked to assess its predictive performance. Prediction error was calculated to assess the predictive performance of the models. Six models plus the SDR model were evaluated. The model of Roberts et al. (J. A. Roberts, F. S. Taccone, A. A. Udy, J.-L. Vincent, F. Jacobs, and J. Lipman, Antimicrob Agents Chemother 55:2704–2709, 2011, https://doi.org/10.1128/AAC.01708-10) performed satisfactorily, with mean and median values of prediction error of 5.1% and 7.5%, respectively, for Amsterdam UMC, Location VUmc, patients, and 12.6% and 17.2% respectively, for OLVG Oost patients. The other models, including the SDR model, yielded high mean values (49.7% to 87.7%) and median values (56.1% to 66.1%) for both populations. In conclusion, only the model of Roberts et al. was able to validly predict the concentrations of vancomycin for our data, whereas other models and standard dosing were largely inadequate. Extensive evaluation should precede the adoption of any model in clinical practice for ICU patients.
Original languageEnglish
Article numbere02543-18
JournalAntimicrobial agents and chemotherapy
Issue number5
Early online date4 Mar 2019
Publication statusPublished - 1 May 2019


  • Antibiotics
  • ICU patients
  • Model validation
  • Population pharmacokinetics
  • Vancomycin

Cite this